Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717494 | 0.97 | GRM5 (0.39) | GRM5CYP1A2KCNH2PDGFRBPDGFRA | |
| SCHEMBL767264 | 0.92 | CYP1A2 (0.35) | GRM5CYP1A2KCNH2 | |
| SCHEMBL1466357 | 0.86 | — | — | |
| SCHEMBL21856654 | 0.77 | — | — | |
| SCHEMBL17818284 | 0.75 | — | — | |
| SCHEMBL3935598 | 0.75 | — | — | |
| SCHEMBL22688070 | 0.75 | — | — | |
| SCHEMBL3823064 | 0.73 | CYP1A2 (0.35) | GRM5CYP1A2KCNH2 | |
| SCHEMBL2106124 | 0.73 | KCNH2 (0.39) | GRM5CYP1A2KCNH2 | |
| SCHEMBL18992849 | 0.72 | GRM5 (0.30) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-8883952-B2 | Optically anisotropic compound and resin composition comprising the same | LG CHEM, LTD. (KR) | 2014-11-11 | — | — | US | disclosed |
| US-8883952-B2 | Optically anisotropic compound and resin composition comprising the same | LG CHEM, LTD. (KR) | 2014-11-11 | — | — | US | disclosed |
| US-8163359-B2 | Retardation film, and polarizing plate and liquid crystal display comprising the same | LG CHEM, LTD. (KR) | 2012-04-24 | — | — | US | disclosed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| US-20100105816-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090169774-A1 | Retardation film, and polarizing plate and liquid crystal display comprising the same | LG CHEM, LTD. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | disclosed |
| EP-1613634-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087714-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105816-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | RER1, SEM1, RCC1 | GRM5 2701/4885CYP1A2 4045/4885KCNH2 3477/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | GRM5 379/4885CYP1A2 3195/4885KCNH2 3285/4885 |
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | IDO1, NAT1, AANAT | GRM5 2465/4885CYP1A2 38/4885KCNH2 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.